Printer Friendly

CISTRON SUES PEPROTECH FOR INTERLEUKIN-1 PATENT INFRINGEMENT

 CISTRON SUES PEPROTECH FOR INTERLEUKIN-1 PATENT INFRINGEMENT
 PINE BROOK, N.J. Dec. 19 /PRNewswire/ -- Cistron Biotechnology, Inc. today announced that it has filed suit in Federal District Court in Newark, N.J. against PeproTech, Inc. of Rocky Hill, N.J., alleging infringement of a patent covering the production of recombinant Interleukin-1 beta (IL-1 beta), to which Cistron holds an exclusive license.
 Cistron was joined in the suit by New England Medical Center Hospitals, Inc., Tufts University, Massachusetts Institute of Technology, and Wellesley College, the licensors of the Interleukin-1 beta technology to Cistron.
 Cistron and the New England institutions are seeking money damages and an injunction against further infringement.
 Under the patent in suit, Cistron holds exclusive license to the production of recombinant human IL-1 beta, a key regulator of the immune system and a member of the family of compounds known as lymphokines.
 Cistron's primary product area is immune system regulators. The company manufactures and sells lymphokine assay kits to pharmaceutical companies and academic institutions in the United States, Europe, and the Far East for cancer, arthritis, and other autoimmune disease research.
 The company is currently expanding its product line and is engaged in research on IL-1 beta inhibitors. An effective inhibitor would reduce inflammation and possible bone and cartilage deterioration in such autoimmune diseases as rheumatoid arthritis and lupus.
 -0- 12/19/91
 /CONTACT: Harold Smith of Hal Smith Associates, 201-305-0244, for Cistron/ CO: Cistron Biotechnology, Inc.; PeproTech, Inc. ST: New Jersey IN: MTC SU:


JT -- NY002 -- 3718 12/19/91 09:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 19, 1991
Words:255
Previous Article:MARRIOTT TO COMPLETE OFFERING OF $200 MILLION IN CONVERTIBLE PREFERRED STOCK
Next Article:LIPOSOME ACQUIRES CLOT-BUSTER TECHNOLOGY FOR HEART ATTACKS; PATENT TO COVER LIPOSOME-ENCAPSULATED FIBRINOLYTIC AGENTS FOR ARTERY REOPENING
Topics:


Related Articles
CISTRON WILL USE EQUITY AGREEMENT PROCEEDS TO EXPAND INTERLEUKIN-1 INHIBITOR RESEARCH PROGRAM
SCHERING-PLOUGH UNIT FILES SUIT CHARGING INFRINGEMENT OF IL-4 PATENT
NEW CANCER GENETHERAPY IS GOAL OF PROJECT BY CISTRON BIOTECHNOLOGY AND GENETIC THERAPY
CISTRON BIOTECHNOLOGY SUES IMMUNEX CORP. OVER INTERLEUKIN-1b PATENT
CISTRON BIOTECHNOLOGY REPORTS SALES INCREASE FOR SECOND QUARTER AND SIX MONTHS
/C O R R E C T I O N -- IMMUNEX/CISTRON/(Correction Notice)
CISTRON ANNOUNCES RESULTS FOR SECOND QUARTER
Henry Grausz Resigns as Chairman and Director of Cistron Biotechnology
Cistron Biotechnology Retains BlueStone Capital Partners as Its Financial Advisor
Cistron Retains Genome Securities as its Investment Banker.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters